PRECISION trial

Author(s):

Manesh R. Patel, MD,Payal Kohli, MD, FACC

Key Takeaways

Difficult-to-treat hypertension involves uncontrolled blood pressure despite using three or more antihypertensive medications, including a diuretic.
It is distinct from resistant hypertension, which is more common and may not include a diuretic in treatment.
This condition affects a smaller subset of patients with high blood pressure and requires a comprehensive management approach.
Lifestyle modifications and evaluation for secondary causes are crucial for optimal management of difficult-to-treat hypertension.

Panelists discuss how the PRECISION trial evaluated aprocitentan, a dual endothelin receptor antagonist (ERA), in patients with resistant hypertension taking 3 antihypertensive medications including a diuretic.

EP: 1.Unmet Needs in HTN: Patient Adherence, Comorbid Conditions, and Prevalence

EP: 2.Current Limitations With Traditional Antihypertensive Drugs

EP: 3.Drug Classes Available to Treat Patients With High Blood Pressure

EP: 4.Difficult-to-Treat Hypertension Treatment Strategies

EP: 5.Current Therapeutic Guidelines for Managing Resistant Hypertension

EP: 6.Endothelin Pathway

Now Viewing

EP: 7.PRECISION trial

Video content above is prompted by the following:

The PRECISION trial was a phase 3, multicenter, randomized study of aprocitentan, a dual ERA, in patients with a systolic blood pressure of 140 mm Hg or higher despite taking 3 antihypertensive drugs, including a diuretic.